Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2751114 | 0.96 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL5527335 | 0.92 | CYP2A6 (0.60) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL5531359 | 0.87 | CYP19A1 (0.56) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL30452018 | 0.87 | CYP2A6 (0.54) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL30338954 | 0.87 | GRM5 (0.56) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL9655784 | 0.87 | CYP2A6 (0.54) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL8882222 | 0.87 | CYP2A6 (0.54) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL12373173 | 0.86 | NPY5R (0.58) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL30416038 | 0.85 | CYP2A6 (0.62) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 | |
| SCHEMBL551225 | 0.85 | CYP2A6 (0.62) | CYP2A6ALDH1A1CYP3A4CYP1A2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109273615-B | Organic light-emitting device | 长春海谱润斯科技有限公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-109273615-A | A kind of organic luminescent device | 长春海谱润斯科技有限公司 | 2019-01-25 | — | — | CN | disclosed |
| CN-109251194-A | A kind of triaizine compounds and its organic luminescent device of the class formation containing fluorenes | 长春海谱润斯科技有限公司 | 2019-01-22 | — | — | CN | disclosed |
| US-8841282-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841282-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841282-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130338119-A1 | Pyrrolidinone Benzenesulfonamide Derivatives as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231655-B1 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMA (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7994166-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994166-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994166-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2231655-A2 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATI VES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009064747-A2 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATI VES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064747-A2 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATI VES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | CYP2A6 2078/4885ALDH1A1 1645/4885CYP3A4 1710/4885 |
| US-20120010416-A1 | PYRROLIDINONE BENZENESULFONAMIDE DERIVATIVES AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | TRPV1, TRPV5, TRPA1 | CYP2A6 2489/4885ALDH1A1 2328/4885CYP3A4 3012/4885 |
| US-20130338119-A1 | Pyrrolidinone Benzenesulfonamide Derivatives as Modulators of Ion Channels | KCNJ2, KCNN2, KCNJ1 | CYP2A6 2654/4885ALDH1A1 2531/4885CYP3A4 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.